Literature DB >> 9865676

Active immunotherapy with allogeneic tumor cell vaccines: present status.

A D Chan1, D L Morton.   

Abstract

This review will concentrate on allogeneic vaccines for melanoma The important principles of melanoma vaccine effectiveness are discussed in detail, followed by a review of the progress of several clinical trials investigating allogeneic vaccines. No therapeutic cancer vaccine has yet been approved for general use by the US Food and Drug Administration. However, much progress has been made in the field of vaccine immunotherapy, especially for the treatment of melanoma. Active immunotherapy with tumor vaccines is progressing rapidly as an emerging option for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865676

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  11 in total

Review 1.  Preventing relapse in melanoma.

Authors:  J Stebbing; M Gore
Journal:  Curr Oncol Rep       Date:  2000-05       Impact factor: 5.075

Review 2.  Immunotherapeutic approaches for the treatment of breast cancer.

Authors:  K L Knutson; K Schiffman; K Rinn; M L Disis
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

3.  Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.

Authors:  Jack C F Liao; Polly Gregor; Jedd D Wolchok; Francesca Orlandi; Diane Craft; Carrie Leung; Alan N Houghton; Philip J Bergman
Journal:  Cancer Immun       Date:  2006-04-21

Review 4.  Improving outcomes in advanced malignant melanoma: update on systemic therapy.

Authors:  Sarah Danson; Paul Lorigan
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Short- and-long term results of intraoperative radiofrequency ablation of liver metastases.

Authors:  G Navarra; A Ayav; J-C Weber; S L Jensen; C Smadga; J P Nicholls; N A Habib; L R Jiao
Journal:  Int J Colorectal Dis       Date:  2005-04-28       Impact factor: 2.571

Review 6.  Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.

Authors:  József Tímár; Andrea Ladányi; István Peták; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

7.  Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.

Authors:  Donald L Morton; Eddy C Hsueh; Richard Essner; Leland J Foshag; Steven J O'Day; Anton Bilchik; Rishab K Gupta; Dave S B Hoon; Mepur Ravindranath; J Anne Nizze; Guy Gammon; Leslie A Wanek; He-Jing Wang; Robert M Elashoff
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

Review 8.  Breast cancer and the immune system: opportunities and pitfalls.

Authors:  T A Plunkett; I Correa; D W Miles; J Taylor-Papadimitriou
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.698

9.  Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes.

Authors:  P Savage; P Cowburn; A Clayton; S Man; A McMichael; N Lemoine; A Epenetos; G Ogg
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

Review 10.  Immune gene therapy in urology.

Authors:  Ingo Kausch; Peter Ardelt; Andreas Böhle; Timothy L Ratliff
Journal:  Curr Urol Rep       Date:  2002-02       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.